Skip to main content

iRhythm Technologies to Participate in Upcoming Investor Conferences in September

SAN FRANCISCO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will present at the following investor conferences in September:

  • Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, at 3:20 pm Eastern Time
  • Wells Fargo 2024 Healthcare Conference on Thursday, September 5, at 8:45 am Eastern Time
  • Baird 2024 Global Healthcare Conference on Tuesday, September 10, at 2:00 pm Eastern time

Those interested in listening to the presentations may do so by accessing the live and archived webcast of the events on the “Events & Presentations” section of the company’s investor website at investors.irhythmtech.com.

About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.

Investor Contact
Stephanie Zhadkevich
investors@irhythmtech.com

Media Contact
Kassandra Perry
irhythm@highwirepr.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  232.87
-1.82 (-0.78%)
AAPL  268.64
-3.77 (-1.38%)
AMD  242.30
-4.51 (-1.83%)
BAC  52.31
-0.30 (-0.57%)
GOOG  287.52
+10.54 (3.81%)
META  604.80
-4.66 (-0.76%)
MSFT  509.05
-1.13 (-0.22%)
NVDA  187.22
-2.95 (-1.55%)
ORCL  220.02
-2.83 (-1.27%)
TSLA  416.62
+12.27 (3.03%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.